智通财经APP讯，海思科(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，经审查，2026年7月受理的HSK60002片符合药品注册的有关要求，同意本品开展临床试验。
HSK60002片是公司自主研发的，具有独立知识产权的口服小分子制剂，拟用于炎症性疾病的治疗。临床前研究数据表明，HSK60002在相关动物模型中表现出显著的药效活性，作用机制明确。综合现有结果，HSK60002具备明确的开发价值和良好的转化前景，有望为临床患者提供一种高效、安全的新型治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.